Analyst Ekaterina Knyazkova from J.P. Morgan maintained a Buy rating on ANI Pharmaceuticals and increased the price target to $115.00 from $95.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ekaterina Knyazkova’s rating is based on the strong growth potential of ANI Pharmaceuticals, particularly driven by its lead product, Cortrophin Gel. The recent launch of a pre-filled syringe has significantly resonated with both patients and physicians, leading to a notable increase in prescriptions and market penetration. This product is expected to continue its upward trajectory, contributing to the company’s valuation and justifying the Buy rating.
Moreover, the ACTH market, where Cortrophin Gel competes, is anticipated to expand as physician awareness grows, providing further opportunities for revenue growth. The company is also benefiting from its generics portfolio and recent acquisitions, which are expected to support both top-line and bottom-line growth, outperforming its peers in the specialty pharmaceutical sector. These factors, combined with a favorable market outlook and strategic positioning, underpin the positive assessment of ANI Pharmaceuticals’ stock.
In another report released on September 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $121.00 price target.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANIP in relation to earlier this year.